WO2003065993A8 - Primary rat hepatocyte toxicity modeling - Google Patents

Primary rat hepatocyte toxicity modeling

Info

Publication number
WO2003065993A8
WO2003065993A8 PCT/US2003/003482 US0303482W WO03065993A8 WO 2003065993 A8 WO2003065993 A8 WO 2003065993A8 US 0303482 W US0303482 W US 0303482W WO 03065993 A8 WO03065993 A8 WO 03065993A8
Authority
WO
WIPO (PCT)
Prior art keywords
primary rat
rat hepatocyte
hepatocyte toxicity
modeling
toxicity modeling
Prior art date
Application number
PCT/US2003/003482
Other languages
French (fr)
Other versions
WO2003065993A2 (en
Inventor
Donna Mendrick
Mark Porter
Kory Johnson
Brandon Higgs
Arthur Castle
Michael Orr
Michael Elashoff
Original Assignee
Gene Logic Inc
Donna Mendrick
Mark Porter
Kory Johnson
Brandon Higgs
Arthur Castle
Michael Orr
Michael Elashoff
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gene Logic Inc, Donna Mendrick, Mark Porter, Kory Johnson, Brandon Higgs, Arthur Castle, Michael Orr, Michael Elashoff filed Critical Gene Logic Inc
Priority to AU2003219713A priority Critical patent/AU2003219713A1/en
Priority to CA002471631A priority patent/CA2471631A1/en
Priority to JP2003565419A priority patent/JP2006502693A/en
Priority to EP03715981A priority patent/EP1578393A4/en
Publication of WO2003065993A2 publication Critical patent/WO2003065993A2/en
Publication of WO2003065993A8 publication Critical patent/WO2003065993A8/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6834—Enzymatic or biochemical coupling of nucleic acids to a solid phase
    • C12Q1/6837—Enzymatic or biochemical coupling of nucleic acids to a solid phase using probe arrays or probe chips
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/142—Toxicological screening, e.g. expression profiles which identify toxicity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Analytical Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
PCT/US2003/003482 2002-02-04 2003-02-04 Primary rat hepatocyte toxicity modeling WO2003065993A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
AU2003219713A AU2003219713A1 (en) 2002-02-04 2003-02-04 Primary rat hepatocyte toxicity modeling
CA002471631A CA2471631A1 (en) 2002-02-04 2003-02-04 Primary rat hepatocyte toxicity modeling
JP2003565419A JP2006502693A (en) 2002-02-04 2003-02-04 Primary rat hepatotoxicity modeling
EP03715981A EP1578393A4 (en) 2002-02-04 2003-02-04 Primary rat hepatocyte toxicity modeling

Applications Claiming Priority (36)

Application Number Priority Date Filing Date Title
US35317102P 2002-02-04 2002-02-04
US60/353,171 2002-02-04
US36353402P 2002-03-13 2002-03-13
US60/363,534 2002-03-13
US37024802P 2002-04-08 2002-04-08
US60/370,248 2002-04-08
US37115002P 2002-04-10 2002-04-10
US37113502P 2002-04-10 2002-04-10
US37113402P 2002-04-10 2002-04-10
US60/371,150 2002-04-10
US60/371,134 2002-04-10
US60/371,135 2002-04-10
US37141302P 2002-04-11 2002-04-11
US60/371,413 2002-04-11
US37360102P 2002-04-19 2002-04-19
US37360202P 2002-04-19 2002-04-19
US60/373,601 2002-04-19
US60/373,602 2002-04-19
US37413902P 2002-04-22 2002-04-22
US60/374,139 2002-04-22
US37837002P 2002-05-08 2002-05-08
US60/378,370 2002-05-08
US37866502P 2002-05-09 2002-05-09
US37865302P 2002-05-09 2002-05-09
US37865202P 2002-05-09 2002-05-09
US60/378,665 2002-05-09
US60/378,653 2002-05-09
US60/378,652 2002-05-09
US39425302P 2002-07-09 2002-07-09
US39423002P 2002-07-09 2002-07-09
US60/394,253 2002-07-09
US60/394,230 2002-07-09
US40768802P 2002-09-04 2002-09-04
US60/407,688 2002-09-04
US44290003P 2003-01-28 2003-01-28
US60/442,900 2003-01-28

Publications (2)

Publication Number Publication Date
WO2003065993A2 WO2003065993A2 (en) 2003-08-14
WO2003065993A8 true WO2003065993A8 (en) 2006-04-27

Family

ID=27739584

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/003482 WO2003065993A2 (en) 2002-02-04 2003-02-04 Primary rat hepatocyte toxicity modeling

Country Status (5)

Country Link
EP (1) EP1578393A4 (en)
JP (1) JP2006502693A (en)
AU (1) AU2003219713A1 (en)
CA (1) CA2471631A1 (en)
WO (1) WO2003065993A2 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1361433A3 (en) * 2002-04-09 2005-02-23 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Method for estimating therapeutic efficacy of tumor necrosis factor (TNF)
WO2005039588A2 (en) * 2003-10-22 2005-05-06 Novartis Ag Methods for determining the risk of developing liver and lung toxicity
US20070218460A1 (en) * 2003-11-27 2007-09-20 Takeda Pharmaceutical Company Limited Method of Estimating Toxicity of Drug
US20060045847A1 (en) * 2004-08-30 2006-03-02 Fernand Labrie Method for determination of anabolic activity
EP1849864A4 (en) * 2005-02-17 2008-08-27 Takeda Pharmaceutical Method for determining phospholipidosis
WO2009018492A2 (en) 2007-07-31 2009-02-05 The Board Of Regents Of The University Of Texas System Micro-rnas that control myosin expression and myofiber identity
US8808979B2 (en) * 2008-05-28 2014-08-19 Basf Se Methods related to liver enzyme induction as a predisposition for liver toxicity and diseases or disorders associated therewith
NZ594365A (en) 2009-02-04 2013-03-28 Univ Texas Dual targeting of miR-208a or miR-208b and miR-499 in the treatment of cardiac disorders or musculoskeletal disorders
JP5804629B2 (en) * 2011-07-29 2015-11-04 株式会社メディクローム Method for evaluating toxicity of chemical substances by gene expression fluctuation analysis
CN107709993A (en) 2015-06-11 2018-02-16 阿斯图特医药公司 Method and composition for diagnosis and the prognosis of injury of kidney and kidney failure

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6372431B1 (en) * 1999-11-19 2002-04-16 Incyte Genomics, Inc. Mammalian toxicological response markers
US20020110808A1 (en) * 2000-01-21 2002-08-15 Reidhaar-Olson John F. Toxicant-induced differential gene expression
AU2001268449A1 (en) * 2000-06-14 2001-12-24 Vistagen, Inc. Toxicity typing using liver stem cells

Also Published As

Publication number Publication date
AU2003219713A8 (en) 2003-09-02
CA2471631A1 (en) 2003-08-14
EP1578393A2 (en) 2005-09-28
EP1578393A4 (en) 2008-03-19
JP2006502693A (en) 2006-01-26
WO2003065993A2 (en) 2003-08-14
AU2003219713A1 (en) 2003-09-02

Similar Documents

Publication Publication Date Title
AU2003272050A1 (en) Stent assembly
AU2003255763A1 (en) Histological assessment
AU2003237447A1 (en) Bioartificial liver system
AU2002952384A0 (en) Structures
AU2003234917A1 (en) Negative resist composition
AU2003281287A1 (en) Toxicity markers
AU2003301232A1 (en) Stent assembly
AU2003253446A1 (en) Self-expandable stent
AU2003226559A1 (en) Expandable well screen
AU2003904025A0 (en) Laryngeal mask
AU2003291889A1 (en) Footing form
EP1457822A3 (en) Positive resist composition
AU2003273924A1 (en) 193nm resist
WO2003065993A8 (en) Primary rat hepatocyte toxicity modeling
AU2003243380A1 (en) Nitrogen-based homo-camptothecin derivatives
AU2003289123A1 (en) Positive resist composition
AU2003287868A1 (en) Stent
AU2003258874A1 (en) Portable urinal for children
AU2003221050A1 (en) Remedy for hypermyotonia
AU2003277581A1 (en) Resist composition
AUPS170702A0 (en) Construction platform
AU2003208347A1 (en) Surface-active photoinitiators
AUPS121202A0 (en) Platform
AU2003202012A1 (en) Toxicity test
AU2003207330A1 (en) Reel-transporting platform

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2471631

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2003565419

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2003715981

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2003715981

Country of ref document: EP

D17 Declaration under article 17(2)a